169 related articles for article (PubMed ID: 36065795)
1. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
Monzo L; Ferreira JP; Cleland JGF; Pellicori P; Mariottoni B; Verdonschot JAJ; Hazebroek MR; Collier TJ; Cuthbert JJ; Pieske B; Edelmann F; Petutschnigg J; Khan J; Ahmed FZ; Girerd N; Bozec E; Díez J; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Rossignol P; Zannad F
ESC Heart Fail; 2022 Dec; 9(6):4352-4357. PubMed ID: 36065795
[TBL] [Abstract][Full Text] [Related]
2. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
[TBL] [Abstract][Full Text] [Related]
4. Race influences the safety and efficacy of spironolactone in severe heart failure.
Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
6. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
[TBL] [Abstract][Full Text] [Related]
7. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
[TBL] [Abstract][Full Text] [Related]
9. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.
Clephas PRD; Radhoe SP; Linssen GCM; Langerveld J; Plomp J; Smits JPP; Nagelsmit MJ; Rocca HB; Brugts JJ
ESC Heart Fail; 2023 Apr; 10(2):1481-1487. PubMed ID: 36738129
[TBL] [Abstract][Full Text] [Related]
10. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
11. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners.
Abensur Vuillaume L; Rossignol P; Lamiral Z; Girerd N; Boivin JM
ESC Heart Fail; 2020 Oct; 7(5):2042-2050. PubMed ID: 32602236
[TBL] [Abstract][Full Text] [Related]
13. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.
Linde C; Qin L; Bakhai A; Furuland H; Evans M; Ayoubkhani D; Palaka E; Bennett H; McEwan P
ESC Heart Fail; 2019 Apr; 6(2):280-290. PubMed ID: 30629342
[TBL] [Abstract][Full Text] [Related]
14. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
Ferreira JP; Zannad F; Butler J; Filipattos G; Ritter I; Schüler E; Kraus BJ; Pocock SJ; Anker SD; Packer M
Eur Heart J; 2022 Aug; 43(31):2984-2993. PubMed ID: 35687107
[TBL] [Abstract][Full Text] [Related]
16. Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans.
Matsushita K; Sang Y; Yang C; Ballew SH; Grams ME; Coresh J; Molnar MZ
PLoS One; 2019; 14(8):e0219899. PubMed ID: 31393910
[TBL] [Abstract][Full Text] [Related]
17. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
[TBL] [Abstract][Full Text] [Related]
18. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
Rossignol P; Girerd N; Bakris G; Vardeny O; Claggett B; McMurray JJV; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Spanyers S; Vincent J; Fay R; Lamiral Z; Solomon SD; Zannad F; Pitt B
Eur J Heart Fail; 2017 Jun; 19(6):792-799. PubMed ID: 27868385
[TBL] [Abstract][Full Text] [Related]
19. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
20. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
